From The Boston Globe · · 1m 10s
Tanzi to receive $41m for Alzheimer’s research
Neuroscientist Rudolph Tanzi gets $41m federal grant to test Alzheimer’s drug combinations.
In brief
Neuroscientist Rudolph Tanzi gets $41m federal grant to test Alzheimer’s drug combinations. Rudolph Tanzi, a neuroscientist at Mass General Brigham, will receive $41 million in federal grants to test five to ten drug combinations for Alzheimer’s disease. Originally reported by The Boston Globe.
MGB neuroscientist gets $41m grant
Rudolph Tanzi, a neuroscientist at Mass General Brigham, will receive up to $41 million in federal health grants to fund a four-year study testing drug combinations for Alzheimer’s.
“Everything’s coming to fruition”
Additional $25m from philanthropists
Tanzi’s research team also receives $25 million from philanthropists to support clinical trials for experimental Alzheimer’s treatments.
Acta Pharmaceuticals raises $24m
Acta Pharmaceuticals, a biotech company co-founded by Tanzi, raised $24 million in seed financing to begin a clinical trial of an experimental Alzheimer’s drug.
Tanzi’s drug screening approach
Tanzi’s team screened 2,000 approved drugs and 4,000 natural compounds to identify five to ten potential drug combinations for Alzheimer’s.
Clinical trial design
The trial will test five drug combinations on 300 patients with Alzheimer’s biomarkers, using placebo groups to measure disease progression.
Tanzi’s vision for prevention
Tanzi hopes daily pills could block Alzheimer’s buildup before cognitive decline, similar to how statins prevent heart disease.
Here's the gist
Rudolph Tanzi, a neuroscientist at Mass General Brigham, will receive $41 million in federal grants to test five to ten drug combinations for Alzheimer’s disease.
